Company profile: Leon Nanodrugs
1.1 - Company Overview
Company description
- Provider of nanotechnology-based drug development, offering access to next-generation nano-formulated drugs, specialized product development of enhanced versions of existing products, and services enabling pre-clinical and clinical formulations for clients’ NCEs or branded drugs. Products include FR-JET System, NANOlab, NANOme, and NANOus for scalable, GMP-compliant nanocarrier manufacturing.
Products and services
- NANOus: Continuous-manufacturing tool engineered for large volumes of nanocarriers, delivering high throughput and seamless scalability with FR-JET technology for efficient, reliable production
- FR-JET System: Proprietary, efficient and reliable nanocarrier production technology central to LEON’s manufacturing systems, providing the core engine for next-generation nano-formulated drug products
- NANOme: GMP-compliant device for aseptic manufacturing of small formulation batches, featuring a fully closed system and direct process transfer from NANOlab for streamlined GMP scale-up
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Leon Nanodrugs
BlueWillow Biologics
HQ: United States
Website
- Description: Provider of intranasal vaccine and adjuvant technologies, including an oil-in-water emulsion Intranasal Adjuvant Technology, NE01 adjuvanted intranasal vaccines, the BW-1010 anthrax vaccine candidate, and a therapeutic peanut allergy vaccine, built on the NanoVax platform to elicit mucosal, cellular, and systemic immunity; also focused on topical antiseptic and anti-infective products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueWillow Biologics company profile →
Elektrofi
HQ: United States
Website
- Description: Provider of a microparticle platform (Hypercon) enabling low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery, alongside formulation development services—covering process development, formulation, analytics, and innovation—and partnership programs with pharmaceutical companies to develop and commercialize subcutaneous biologic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elektrofi company profile →
scPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical products for subcutaneous delivery, including FUROSCIX, a furosemide injection for subcutaneous use to treat congestion due to fluid overload in adult patients with heart failure, and an investigational subcutaneous ceftriaxone delivery system for outpatient antibiotic therapy. Offers clinical trials, supports investigator-sponsored studies, educational grants, and medical information services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full scPharmaceuticals company profile →
Virpax Pharmaceuticals
HQ: United States
Website
- Description: Provider of intranasal and topical therapeutics for pain, epilepsy, and viral inhibition, including: Probudur, a single-injection liposomal bupivacaine for extended post-operative pain; Envelta, intranasal enkephalin for acute/chronic and cancer pain; NobrXiol, intranasal CBD for rare pediatric epilepsy; AnQlar, intranasal spray to inhibit influenza/SARS-CoV-2; and Epoladerm, topical diclofenac spray film for osteoarthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Virpax Pharmaceuticals company profile →
Xanadu Bio
HQ: United States
Website
- Description: Provider of nanoparticle delivery technology for mRNA and other nucleic acids, using PACE platform technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xanadu Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Leon Nanodrugs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Leon Nanodrugs
2.2 - Growth funds investing in similar companies to Leon Nanodrugs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Leon Nanodrugs
4.2 - Public trading comparable groups for Leon Nanodrugs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →